Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y educación

Enviado por remote_content el Lun, 21/10/2024 - 08:43

Enfermedades infecciosas

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

Consensus recommendations based on evidence for abdominal sepsis in the pediatric and adult population of colombia. Infectio,

Julio 30, 2022

Enfermedades infecciosas

Cardiovascular risk factors and comorbidities in people living with HIV: A cross-sectional multicenter study from Colombia comorbidities in a Colombian PLWHIV population. Int J STD AIDS.

Mayo 3, 2022

Enfermedades infecciosas

Long-term consequences of the misuse of ivermectin data. Lancet Infect Dis.

Octubre 18, 2021

21 Octubre, 2024